Truist raises Globe Life stock price target to $185 on higher EPS outlook

Truist raised its price target on Globe Life to $185 from $180 and lifted its 2026/2027 EPS estimates to $15.60 and $16.70, respectively, while keeping a Buy rating. Globe Life also reported Q1 2026 EPS of $3.43 versus $3.48 expected, a 1.44% miss, though revenue matched forecasts at $1.56 billion. The mixed update appears modestly positive overall, with the higher target offset by the small earnings miss.

Analysis

The key signal here is not the modest earnings miss; it is that the multiple reset is being driven by higher forward EPS while the stock is already priced near peak levels. That combination tends to compress upside unless the company can keep out-earning estimates for several quarters in a row, because insurers at full valuation are punished less for stability than for any deceleration in growth.

Second-order, the earnings raise implies the market may be underappreciating how much of the rerating is already embedded. If the stock is now trading close to the new implied target multiple, the next leg likely depends on either continued estimate revisions or a broader rotation into defensive financials. Absent that, the name can drift sideways for months even if fundamentals remain fine.

The contrarian angle is that the “Buy” case may be more about quality and balance-sheet durability than near-term alpha. That makes GL attractive as a relative long only if the market is rewarding defensives and penalizing more cyclical financials; otherwise, the risk/reward from current levels is asymmetrically muted. The cleanest bearish catalyst would be any sign of claims normalization, slower premium growth, or a break in the upward EPS revision trend over the next 1-2 quarters.

Key Decisions for Investors

• Hold/trim GL into strength: upside from current levels looks limited unless consensus EPS keeps rising; consider reducing exposure on rallies toward the mid-$150s and waiting for a better entry if the stock pulls back 5-8%.
• Relative-value long GL vs. a more cyclical financial insurer/financials basket over the next 1-2 quarters: if the market stays risk-off, GL’s defensive profile should outperform, but the pair should be sized for a low-beta grind rather than a momentum breakaway.
• Sell near-dated out-of-the-money GL calls against a long stock position if you own it: the stock is already close to a valuation ceiling implied by the new target, so premium harvesting is favorable unless there is a fresh earnings revision catalyst.
• Avoid initiating a fresh outright long here unless you have a 6-12 month horizon: the risk/reward is better on pullbacks than chasing after a target raise when the stock is near all-time highs.
• Set a watchpoint on the next two earnings prints: if EPS revisions stop moving up, the multiple should compress toward low-double-digit norms rather than expand, making a tactical short or put spread more attractive on any failed breakout.